Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery (HARVITA)

March 13, 2024 updated by: Medical University Innsbruck

Randomized Comparison of HARVesting the Left Internal Thoracic Artery in a Skeletonized Versus Pedicled Technique: the HARVITA Trial

Internal thoracic arteries can be harvested in skeletonized or pedicled technique. Latest research has posed a potential adverse effect of skeletonizing the internal thoracic arteries on graft patency rates and clinical outcome. Prospective, randomized, multi-centre trials are necessary to investigate the impact of harvesting technique of left internal thoracic artery (LITA) on graft patency rates and clinical outcome after coronary artery bypass grafting.

The HARVITA trial compares skeletonized and pedicled harvesting technique of LITA regarding graft patency rates and patient survival.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

1350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Graz, Austria
        • Not yet recruiting
        • Medical University of Graz
        • Contact:
          • Daniel Zimpfer, Univ. Prof. Dr.
      • Innsbruck, Austria
        • Recruiting
        • Medical University of Innsbruck
        • Contact:
          • Hannes Abfalterer, Dr. med. univ.
      • Vienna, Austria
        • Not yet recruiting
        • Medical University of Vienna
        • Contact:
          • Sigrid Sandner, Assoz. Prof. Priv. Doz. Dr.
      • Essen, Germany
        • Not yet recruiting
        • University of Duisburg-Essen
        • Contact:
          • Matthias Thielmann, Univ. Prof. Dr.
      • Freiburg, Germany
        • Not yet recruiting
        • University of Freiburg
        • Contact:
          • Martin Czerny, Univ. Prof. Dr.
      • Gießen, Germany
        • Not yet recruiting
        • University Hospital Giessen
        • Contact:
          • Andreas Böning, Univ. Prof. Dr.
      • Jena, Germany
        • Not yet recruiting
        • University of Jena
        • Contact:
          • Torsten Doenst, Univ. Prof. Dr.
      • Bern, Switzerland
        • Not yet recruiting
        • University Hospital Bern
        • Contact:
          • Matthias Siepe, Univ. Prof. Dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

Primary isolated CABG patients with multi-vessel disease (defined as ≥70 % stenosis of the left anterior descending artery (LAD) and ≥50% stenosis of circumflex and right coronary territory, with or without a ≥50% stenosis of the left main artery).

Exclusion criteria:

  • Age > 80 years
  • Planned CABG without LITA use
  • Preoperative mediastinal radiation therapy
  • Emergency operation
  • Minimal invasive coronary artery bypass surgery
  • Any concomitant cardiac or non-cardiac procedures
  • Previous cardiac surgery
  • Known contrast agent allergy
  • Severe stenosis of the left subclavian artery/ left-sided subclavian steal syndrome
  • Chronic kidney disease (GFR <60ml/min/1.73m²)
  • Life expectancy of less than 5 years
  • Pregnancy
  • Hyperthyroidism
  • Iodine allergy

Intraoperative exclusion criteria:

  • Y/T graft off the LITA graft
  • LITA sequential grafting
  • LITA target vessel other than LAD

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: skeletonized harvesting technique
In skeletonized harvesting technique, only the left internal artery itself is harvested.
In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
Active Comparator: pedicled harvesting technique
In pedicled harvesting technique the left internal thoracic artery, it's accompanying veins and parts of the endothoracic fascia is harvested, creating a 1-2 cm broad pedicle.
In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death or LITA graft occlusion in cCTA or invasive angiography within 2 years (+/- 3 months) after surgery.
Time Frame: 2 years (+/- 3 months) after surgery

The primary endpoint will be compared between the two treatment groups using Kaplan-Meier graphs and a center stratified two sample log-rank test. In addition, Cox proportional hazards regression analysis adjusting for clinically relevant confounders will be performed. Hazard ratios and their 95% confidence intervals will be estimated.

LITA graft occlusion is defined as the absence of contrast detection in the lumen of the graft indicating a 100% occlusion of LITA graft.

2 years (+/- 3 months) after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
composite outcome of all-cause death, myocardial infarction and repeated revascularization
Time Frame: 1 year, 2 years and 5 years after surgery
The composite outcome of all-cause death, myocardial infarction and repeated revascularization will be compared with Kaplan-Meier graphs together with log-rank testing.
1 year, 2 years and 5 years after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hannes Abfalterer, Dr. med. univ., Medical University Innsbruck
  • Principal Investigator: Nikolaos Bonaros, Univ. Prof. Dr., Medical University Innsbruck

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 12, 2024

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2031

Study Registration Dates

First Submitted

June 22, 2023

First Submitted That Met QC Criteria

July 3, 2023

First Posted (Actual)

July 5, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

June 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on skeletonized harvesting technique

Subscribe